ABN AMRO Fund

ABN AMRO is a banking institution that serves retail, private, and commercial customers in the Netherlands and internationally. The bank offers a comprehensive range of financial products and services, supported by in-depth expertise and extensive knowledge across various sectors. ABN AMRO is committed to adapting to the evolving market landscape and the changing needs of its customers, prioritizing transparency and service excellence in its operations. Additionally, the bank manages the ABN AMRO Sustainable Impact Fund, which invests in companies and early-stage projects within key transition sectors, focusing on energy, circular economy, and social impact initiatives. With a total commitment of EUR 425 million, the fund aims to support and accelerate sustainability transitions through direct equity investments.

Gaetano Giuffrè

Investment Manager

66 past transactions

ETPA

Venture Round in 2024
ETPA operates a trade platform dedicated to short-term electricity trading, emphasizing the capacity of trade participants. The platform allows users to engage in trading for themselves or via third parties, offering various contract options, including intraday, day ahead, week, and weekend trades. ETPA aims to facilitate a transition to a more sustainable energy future by providing an independent and transparent trading environment. This enables participants to optimize their energy portfolios, leverage flexibility in their production processes, and enhance liquidity in the short-term electricity market.

Zenobe Energy

Debt Financing in 2024
Zenobe Energy Limited specializes in the design and manufacture of battery storage assets primarily for electric bus operators, utilities, and industrial and commercial enterprises. Established in 2016 and headquartered in London, the company provides grid-connected energy storage solutions, frequency balancing services, and second-life battery services, which involve repurposing batteries after their initial use. Additionally, Zenobe Energy offers charging services to support its clients in managing their energy needs and reducing their environmental impact. Formerly known as Battery Energy Storage Solutions Limited, the company rebranded in March 2019 to reflect its broader focus on energy storage and sustainability.

BUX

Acquisition in 2023
BUX is a fintech company founded in 2014 and headquartered in Amsterdam, Noord-Holland. It specializes in developing mobile applications that facilitate commission-free investing, making financial markets more accessible and affordable for both new and experienced investors. The company’s platform allows users to invest in stocks, exchange-traded funds (ETFs), and real cryptocurrencies without incurring transaction fees. By reducing the barriers to entry in the investment space, BUX aims to empower individuals to engage with financial markets more intuitively and conveniently.

Spectral

Venture Round in 2023
Spectral is an end-to-end system integrator specialized in developing and implementing software and hardware solutions focused on smart energy applications.

IGNIS Energía

Debt Financing in 2023
IGNIS Energía is a company specialized in the management and representation of cogeneration plants.

NorSun

Private Equity Round in 2023
NorSun is a Norwegian company specializing in the manufacture of high-performance monocrystalline silicon ingots and wafers for the solar energy industry. The company utilizes the Czochralski process to produce its products, which involves melting polysilicon and shaping it into blocks that are then sliced into thin wafers. These wafers are supplied to leading manufacturers of high-efficiency solar cells, who prioritize quality and innovation in their production processes. NorSun operates modern production facilities in Årdal, Norway, and Vantaa, Finland, with an annual production capacity projected to exceed 200 MWp. The company is dedicated to enhancing economies of scale and advancing technology to improve the efficiency and affordability of solar energy conversion.

Colibri Energy

Venture Round in 2023
Colibri Energy is an innovator and producer of lithium technology for GSE and material handling. It is our mission to build a product, second to none in performance and quality. With a positive track record over five years in the harshest conditions and busiest hubs, Colibri doesn’t rest developing innovations to help our global partners tackle the challenges of the future.

Fairphone

Venture Round in 2023
Fairphone is a company founded in 2010 in Amsterdam, specializing in the production of ethically sourced smartphones that facilitate calling, texting, and internet browsing. The company emphasizes transparency in its supply chain, ensuring that the materials used in its devices are sourced responsibly. This commitment allows consumers to contribute to positive social and environmental outcomes throughout the lifecycle of their smartphones. By prioritizing ethical practices, Fairphone aims to redefine the smartphone industry and promote sustainability among its users.

Exasun

Venture Round in 2022
Exasun B.V. is a Dutch company engaged in the development, manufacturing, and marketing of solar photovoltaic panels. Established in 2012 and based in The Hague, the company produces high-efficiency glass-glass solar modules, including black glass, black roof, X-façade, X-tile, and X-colour models. These solar panels are designed for a variety of applications, such as flat roofs, slanted roofs, new constructions, renovations, and building-integrated photovoltaics. Exasun has advanced its production capabilities through collaboration with suppliers, knowledge institutions, and Dutch machine builders. The company markets its products through a network of premium installers, focusing on enhancing both the efficiency and aesthetics of solar energy solutions.

Wakuli

Seed Round in 2022
Wakuli is a retailer specializing in specialty coffee, focusing on delivering freshly roasted beans and coffee powder directly from farmers to consumers. By eliminating intermediaries, Wakuli ensures that customers receive fresh coffee within a week of roasting, allowing them to experience the full range of flavors inherent in lighter roasts. The company is committed to fair pricing for farmers, enabling them to earn a better income while providing consumers with affordable, high-quality coffee. This direct-to-consumer model enhances the coffee-drinking experience while supporting sustainable practices in the coffee industry.

Lendahand

Seed Round in 2022
Lendahand is an online impact investing platform that focuses on crowdfunding to support small and medium-sized enterprises (SMEs) in emerging markets. By connecting investors with entrepreneurs, Lendahand facilitates loan funding that enables businesses in developing countries to grow and thrive. Investors have the opportunity to earn a profit while contributing to social and sustainable development, thereby playing a role in poverty eradication. The platform is designed to provide a mutually beneficial relationship where entrepreneurs receive the necessary financial support for their projects, and investors receive their funds back with interest.

In Ovo

Series B in 2022
In Ovo focuses on improving animal welfare and efficiency within the poultry industry by addressing the longstanding issue of culling one-day-old male chickens in hatcheries. The company has developed a biotechnological solution that employs biomarkers for gender screening early in the breeding process. This innovation eliminates the need for the stressful manual gender sorting currently in use, significantly reduces energy consumption and carbon dioxide emissions in hatcheries, and prevents the unnecessary killing of male chicks. By enhancing both the sustainability and efficiency of hatcheries, In Ovo aims to create a more humane approach to poultry production.

Envision

Venture Round in 2021
Envision Technologies B.V., founded in 2017 and based in Delft, the Netherlands, specializes in developing a visual recognition platform aimed at enhancing accessibility for visually impaired individuals. The company's Accessibility-as-a-Service platform offers a range of features, including text reading, face and object recognition, scene description, and color detection. This technology is designed to empower users by enabling them to navigate their environments independently, facilitating everyday activities such as shopping, using public transport, and social interactions. Envision's solution is versatile, deployable across various devices, including smartphones, IoT devices, and cloud platforms, effectively merging assistive technology with artificial intelligence to foster inclusivity for those with visual impairments.

Picnic

Debt Financing in 2019
Picnic is an innovative online supermarket that focuses on delivering groceries directly to consumers' homes at competitive prices without any delivery fees. The company's platform enables users to conveniently place orders for fast-moving consumer goods, sourcing products from local suppliers such as bakers and greengrocers. Picnic utilizes electric vehicles for its delivery operations, ensuring an environmentally friendly approach to grocery shopping. By combining technology with a modern take on traditional home delivery services, Picnic aims to provide a seamless and cost-effective shopping experience for its customers.

Fairphone

Debt Financing in 2018
Fairphone is a company founded in 2010 in Amsterdam, specializing in the production of ethically sourced smartphones that facilitate calling, texting, and internet browsing. The company emphasizes transparency in its supply chain, ensuring that the materials used in its devices are sourced responsibly. This commitment allows consumers to contribute to positive social and environmental outcomes throughout the lifecycle of their smartphones. By prioritizing ethical practices, Fairphone aims to redefine the smartphone industry and promote sustainability among its users.

Exasun

Venture Round in 2018
Exasun B.V. is a Dutch company engaged in the development, manufacturing, and marketing of solar photovoltaic panels. Established in 2012 and based in The Hague, the company produces high-efficiency glass-glass solar modules, including black glass, black roof, X-façade, X-tile, and X-colour models. These solar panels are designed for a variety of applications, such as flat roofs, slanted roofs, new constructions, renovations, and building-integrated photovoltaics. Exasun has advanced its production capabilities through collaboration with suppliers, knowledge institutions, and Dutch machine builders. The company markets its products through a network of premium installers, focusing on enhancing both the efficiency and aesthetics of solar energy solutions.

JustPremium

Debt Financing in 2017
JustPremium B.V. is an advertising exchange specializing in high-impact display and video advertising. The company provides a variety of advertising formats, including video wallpaper, lightboxes, and mobile advertising solutions. It operates a programmatic platform that combines creativity, media, and technology to enhance brand visibility in a competitive digital landscape. With access to over 15 billion impressions each month, JustPremium connects a vast network of premium publishers with leading global brands, reaching more than 900 million unique visitors across 25 countries. Headquartered in Amsterdam, the company also has regional offices in cities such as London, Hamburg, Madrid, and Dubai. Its real-time bidding system allows advertisers to target specific audiences effectively, ensuring impactful cross-screen user experiences.

Goodnight Midstream

Debt Financing in 2016
Goodnight Midstream, LLC, based in Dallas, Texas, specializes in fluids management services for oil and gas producers across North Dakota, Wyoming, Texas, and New Mexico. Founded in 2011, the company has established itself as a leading independent provider of water gathering and disposal services, particularly in the Bakken region. Goodnight Midstream operates an extensive network that includes over 150 miles of saltwater gathering pipelines and 16 saltwater disposal facilities. The company focuses on the gathering and disposal of produced saltwater, helping clients minimize environmental impact, enhance health and safety, and reduce lease operating expenses.

TradeBridge

Debt Financing in 2016
TradeBridge, founded in 2013 and headquartered in London, operates internationally with offices in the UK, France, Singapore, and China. The firm specializes in providing a variety of financing solutions, including invoice finance, trade finance, pharmacy finance, and supply chain finance, primarily targeting the e-commerce and healthcare sectors. TradeBridge collaborates with diverse businesses and funding partners to deliver working capital solutions tailored for entrepreneurial and growing enterprises, with a focus on revenue-based finance and payables finance to meet the demands of a rapidly evolving market.

Barge Master

Private Equity Round in 2015
Relatively small vessel motions can have a large impact on the safety and workability of offshore operations. Barge Master provides the solution to deal with these sea induced vessel motions during offshore operations. Barge Master specializes in developing motion compensation systems meant to improve the safety and workability of offshore operations. By eliminating vessel motions Barge Master ensures safe and cost effective lifting operations in offshore conditions. By increasing the workability, costs will be reduced significantly. Barge Master systems are developed together with a number of selected technology partners. These partners are recognized as leading in their respective industries, all with outstanding track records, allowing us to ensure the highest quality in motion compensation systems. The innovative nature of the Barge Master concept is recognized by the European patent office, industry specialists and the Dutch Government through its innovations-office.

Ensartech

Venture Round in 2011
Ensartech is engages in mastering high temperature processes to process highly polluted waste and residual streams of various industries and convert them into various types of energy.

Evenementenhal Hardenberg

Venture Round in 2008
Evenementenhal Hardenberg operates trade fairs and marketing events.

BioVex Group

Series E in 2007
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

SPS Commerce

Series C in 2007
SPS Commerce, Inc. is a provider of cloud-based supply chain management solutions, catering to retailers, suppliers, grocers, distributors, and logistics firms globally. The company's platform enhances order management and fulfillment, sell-through performance, and item sourcing. Key offerings include the Trading Partner Community solution, which facilitates onboarding new vendors and managing supply chain changes, and the Trading Partner Fulfillment solution that automates fulfillment processes. Additionally, SPS Commerce provides the Trading Partner Assortment solution for managing item attributes, as well as analytics applications that improve supply chain visibility. The company also offers sourcing solutions to connect retailers with suppliers and other trading partners. Other services include barcode labeling and packaging applications that streamline operations. SPS Commerce primarily serves small to mid-sized suppliers, retailers, distributors, and third-party logistics providers, utilizing a sales force focused on these segments. Founded in 1987 and headquartered in Minneapolis, Minnesota, SPS Commerce has evolved from its original name, St. Paul Software, Inc., to its current identity in 2001.

Sauna360 Group

Acquisition in 2006
Sauna360 is a manufacturer specializing in sauna, steam, and infrared bathing systems and accessories for both residential and professional applications. The company offers a comprehensive range of products designed to enhance wellness experiences, including rooms, heaters, control panels, steam generators, and interior surfaces. All products are crafted using high-quality materials that ensure durability and efficiency, catering to the diverse needs of customers. Sauna360 aims to provide innovative and stylish solutions that contribute to superior sauna sessions and rejuvenating experiences.

PanGenetics

Series B in 2006
PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases. PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employs a lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients

Xention

Series B in 2005
Xention Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that focuses on discovering and developing innovative ion channel-modulating drugs. Founded in 2002, the company aims to address significant unmet medical needs by creating therapies for conditions such as atrial fibrillation, overactive bladder, pain, and autoimmune diseases. Xention develops drug candidates that target two novel yet well-characterized ion channels, striving to produce breakthrough therapies that enhance treatment options in these areas. The company, originally known as Xention Discovery Ltd., rebranded to Xention Limited in October 2006.

Glud & Marstrand

Acquisition in 2005
Glud & Marstrand is a Denmark-based manufacturer specializing in metal packaging for the food industry. The company produces a variety of metal and tin packaging solutions, including cans and containers, designed for food, beverages, household products, electronics, pharmaceuticals, and chemicals. In addition to its packaging products, Glud & Marstrand offers design services and packaging technology, catering to diverse market needs.

Alantos Pharmaceuticals

Series B in 2005
Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting conditions such as osteoarthritis, inflammation, and type II diabetes. Established in 2002 and located in Cambridge, Massachusetts, the company specializes in innovative therapeutic approaches, including Dipeptidyl and Peptidase IV inhibitors. In addition to its core areas, Alantos explores various tissue remodeling pathways to address a range of medical issues, including rheumatoid arthritis, liver fibrosis, cardiovascular conditions, chronic wound healing, and cancer.

CircuLite

Series A in 2004
CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.

FlowMedica

Series C in 2004
FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

Bluebird Bio

Venture Round in 2004
Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Bluebird Bio

Series A in 2004
Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Ethel Austin

Acquisition in 2004
Ethel Austin is a British clothing retailer that operates a chain of retail clothing stores across the United Kingdom. The company specializes in offering a variety of clothing products aimed at a diverse customer base. With a focus on accessibility and affordability, Ethel Austin provides a range of apparel designed to meet the needs of its shoppers. Through its physical storefronts, the company aims to deliver a convenient shopping experience while maintaining a commitment to quality and style in its product offerings.

Cilian AG

Series B in 2004
Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. While Ciliates secrete a number of therapeutically relevant enzymes with high expression rates by nature, recombinant proteins are produced by Ciliates using genetically modified cells. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.

Accelerated Technologies

Series B in 2004
Accelerated Technologies, Inc. (ATI), a New York based partnership model for the creation and acceleration of cardiovascular devices.

STIGA S.p.A.

Acquisition in 2003
STIGA S.p.A. is the largest manufacturer of lawn mowers and gardening equipment. The brand STIGA is part of the company STIGA Group (formerly GGP Group), that also includes the four local brands Mountfield, Atco, Alpina and Castelgarden. The Group is present in more than 70 major nations worldwide and has its headquarter located in Castelfranco Veneto, Treviso (Italy). Moreover, it can count on 12 subsidiaries and representative offices all around Europe.

BioVex Group

Series C in 2003
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Ardana Bioscience

Series B in 2003
Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

Acorda Therapeutics

Series B in 2003
Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders in the United States and internationally. The company’s primary product, Ampyra (dalfampridine), is an oral medication approved to enhance walking in patients with multiple sclerosis. Additionally, Acorda markets Inbrija, an inhalation powder for the treatment of OFF periods in individuals with Parkinson's disease. The company's pipeline includes rHIgM22, which has completed Phase I trials for multiple sclerosis, and Cimaglermin alfa, currently in Phase Ib trials for heart failure. Acorda has established a collaboration with Biogen for the development and commercialization of Ampyra. Founded in 1995 and based in Ardsley, New York, Acorda Therapeutics aims to improve the quality of life for those affected by neurological conditions.

Acadia Pharmaceuticals

Series F in 2003
Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs for central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for its product NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is actively advancing pimavanserin through Phase III clinical trials for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as exploring its use for major depressive disorder. The company operates two subsidiaries in Sweden and Denmark and is committed to discovering novel treatments for conditions such as Alzheimer's and schizophrenia, while also seeking to in-license or acquire complementary products. Acadia holds several patent applications related to its proprietary technology, including innovative methods for drug discovery and development.

Impella Cardiosystems

Venture Round in 2003
Impella CardioSystems AG, based in Aachen, Germany, develops, manufactures and markets minimally invasive cardiovascular support systems for numerous indications in the fields of cardiology and coronary surgery. The company's technology is protected by more than 30 European and international patents, and currently employees 50 individuals. For the last 2 years Impella has been affiliated with and assisted by Accelerated Technologies, Inc (ATI), a medical device accelerator located in Hackensack, NJ.

SPS Commerce

Series A in 2002
SPS Commerce, Inc. is a provider of cloud-based supply chain management solutions, catering to retailers, suppliers, grocers, distributors, and logistics firms globally. The company's platform enhances order management and fulfillment, sell-through performance, and item sourcing. Key offerings include the Trading Partner Community solution, which facilitates onboarding new vendors and managing supply chain changes, and the Trading Partner Fulfillment solution that automates fulfillment processes. Additionally, SPS Commerce provides the Trading Partner Assortment solution for managing item attributes, as well as analytics applications that improve supply chain visibility. The company also offers sourcing solutions to connect retailers with suppliers and other trading partners. Other services include barcode labeling and packaging applications that streamline operations. SPS Commerce primarily serves small to mid-sized suppliers, retailers, distributors, and third-party logistics providers, utilizing a sales force focused on these segments. Founded in 1987 and headquartered in Minneapolis, Minnesota, SPS Commerce has evolved from its original name, St. Paul Software, Inc., to its current identity in 2001.

Pieris AG

Series A in 2002
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.

BEELINE Technologies

Venture Round in 2002
BEELINE Technologies is the global software partner for clients requiring integrated autonomous control and navigation technologies for land-based vehicles. Quality assured and agile, we develop integrated solutions across all industries. For more than 10 years, the company’s diverse and experienced teams have worked with original equipment manufacturers and technology organisations, to deliver flexible, leading-edge technology solutions for self-propelled, ground-based vehicles. BEELINE is proud of its pioneering spirit, and its innovative, autonomous solutions are used extensively around the world. BEELINE’s commitment to product innovation continues through its investment in sophisticated technology research and development programs that deliver outstanding solutions to our clients. BEELINE is in an exciting growth phase that continues to build value for its existing clients, whilst applying that experience, knowledge, and capability to new industries and technologies.

AM Pharma

Series B in 2002
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Ardana Bioscience

Series A in 2001
Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

UpShot Corporation

Series E in 2001
UpShot.com is the market’s provider of Internet-based sales force automation services. Their Web-based solution brings the power of the Internet to businesses that need first-day productivity from a robust, collaborative solution, without the hassle of building and maintaining it themselves. Since its introduction in August, 1999, the UpShot.com hosted Web application has become the sales management solution for more than 6000 businesses because it provides robust application features, superior ease of use, and full-strength data security—without the pain of building or maintaining the supporting IT infrastructure. UpShot.com is based in Mountain View, California, and is funded by venture capital firms, leading companies, and private investors. Since the company launched in January 1997, their aim has been to build, sell, and support a family of Web-based sales solutions that prospective customers want and actual customers love. They understand that the Web is powering the future. And they are dedicated to leading the way in Web-based sales management.

Drug Abuse Sciences

Series A in 2001
Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

Tradiant

Venture Round in 2000
Tradiant is focused on global transportation execution -- that vital link in the overall global supply chain. Founded by a team of Silicon Valley and Transportation Industry professionals, Tradiant provides the technology platform, products, and global connectivity to power online commerce for the transportation industry.

EcomXML

Venture Round in 2000
EcomXML is a leading e-commerce solution provider for business-to-business (B2B) enterprise integration. EcomXML provides companies with enterprise integration solutions to link their buyers, suppliers and e-commerce portals together to streamline their e-business in real-time through the Internet. EcomXML utilizes open XML technology to achieve both inter-company and intra-company integration regardless their existing technology infrastructure.

BondDesk Group

Venture Round in 2000
BondDesk Group LLC is a leading financial technology company specializing in fixed income solutions for over 2,000 investment firms, including major broker-dealers in North America. It operates the BondDesk Alternative Trading System (ATS), which provides clients access to a substantial pool of live offerings, facilitating approximately 15,000 to 20,000 transactions daily. The platform benefits traders, financial advisors, and individual investors by offering commingled inventory from a wide network of broker-dealers. BondDesk's flagship product, the BondWorks Wealth Management Platform, delivers advanced portfolio management, price transparency, and compliance solutions. With its user-friendly design, BondWorks caters to both novice and experienced fixed income users, enabling them to efficiently find bonds and execute trades while utilizing sophisticated analytics and decision-support tools directly from their desktops.

Aucxis Corporation

Venture Round in 2000
aucxis is the world's leading e-business services provider to perishable commodity marketplaces. The company has streamlined electronic commerce processes for auction houses, buyers and sellers, eliminating inefficiencies and boosting online trading capabilities. aucxis provides Internet-enabled real-time electronic trading systems and is adding financial, logistics, information and infrastructure services through strategic partnerships with industry leaders.

Xpede

Series B in 2000
Xpede focuses on enhancing relationships between financial institutions and their customers through innovative web-based solutions. As an Application Service Provider, it enables lenders to establish a personalized online presence for loan origination, closure, and servicing. By leveraging a highly scalable Java-based application server, Xpede offers a customizable platform that integrates seamlessly with existing back-end systems, re-engineering workflows to improve operational efficiency. The company's software solutions are designed to optimize online transactions and expand product offerings for financial institutions. Founded in 1998 and backed by venture capital from notable investors, Xpede combines expertise from both the financial services and information technology sectors, positioning itself as a leader in e-commerce solutions within the financial market. The company provides continuous management and hosting of its solutions in a state-of-the-art data center, ensuring reliable service for its clients.

LNG Holdings

Private Equity Round in 2000
LNG Holdings S.A. offers local loop, national and international managed bandwidth services plus a new generation of telephony, Internet and online IT solution bundles for commercial businesses and operators. The company's service spectrum ranges from fiber-optic transmission circuits to high bit-rate IP services and even co-location services at all its PoPs. LNG Holdings S.A aims to become a pre-eminent provider of managed bandwidth services throughout Europe, and has rapidly established itself as a leader in Europe's largest telecommunications market, Germany, as well as building extensive networks in France and Spain and links to other major European cities, including Amsterdam, Brussels and London.

Cycore

Venture Round in 2000
Cycore is a privately held graphics software company based in Uppsala, Sweden. Cycore was founded in 1996 by a group of creative engineers, led by Jerry Pettersson. Cycore currently employs 78 people worldwide (as of February 2000) and specializes in the development of 3D technologies for the Internet, as well as special effects software and animation solutions for film makers, designers and corporations worldwide.

Telenisus

Series B in 2000
Telenisus is a technology firm that provides e-commerce internet solutions to its clients. It was founded in 1999 and is based in Illinois.

BeXcom

Venture Round in 2000
BeXcom, a privately held corporation founded in 1996, operates a global network of eCommerce hubs in the world's major trading zones. This global transaction infrastructure enables companies and exchanges to conduct business electronically locally or with multiple trading partners around the world. BeXcom's Commerce Service Provider model provides and maintains all the required hardware and software to operate centralized B2B eCommerce solutions for their users. By building on the BeXcom infrastructure, supply chains, vertical markets and market makers can quickly implement or dramatically extend their eCommerce capabilities to cover the complete range of purchasing processes, from RFQ to settlement. BeXcom is the first company to integrate global financial, logistics, and certificate authority services into a global eCommerce infrastructure, ensuring all transactions are safe, secure, and verifiable. BeXcom helps their customers streamline business processes, reduce costs, expand markets and add value to their business by delivering the full potential of B2B eCommerce.

IMX Exchange

Venture Round in 2000
IMX Exchange is an online marketplace for the wholesale mortgage industry.

Corechange

Series B in 2000
The company provides enterprise portal software for the deployment and management of Intranet and extranet portals. The company's Coreport enterprise portal software allows businesses to provide all their stakeholders with a single, secure point of unified and personalized access to content, applications, processes, and services from any wired or wireless device.

clickNsettle.com

Venture Round in 2000
clickNsettle.com is a subsidiary of National Arbitration and Mediation, specializing in dispute resolution services through its online platform. It facilitates the settlement of disputes across various legal areas, including personal injury, contracts, construction issues, medical malpractice, commercial liability, employment practices, and environmental conflicts. The company handles over 10,000 cases each year, employing a network of Hearing Officers and utilizing electronic case management software to streamline the resolution process. By providing accessible and efficient solutions for conflict resolution, clickNsettle.com aims to simplify the settlement process for its users.

Cortera

Venture Round in 1999
Cortera, Inc. is a provider of business-to-business analytics and cloud-based risk management solutions, specializing in payment and purchase behavior data for both public and private companies. The company tracks $1.6 trillion in business-to-business purchases across 45 spend categories, delivering insights on 20 million U.S. business locations. Its offerings include Cortera Pulse, which monitors credit risk and key events; Boost, which appends scores and insights about customers and suppliers; and Cortera Decisions, an automated scorecard platform. Additionally, Cortera provides eCredit for credit scoring and collections automation, Cortera Traits for real-time statistical modeling, and Connect, an XML web service for accessing proprietary data. With a focus on helping companies understand their customers and partners, Cortera’s solutions enhance revenue generation, improve sales and marketing effectiveness, and mitigate risk. Founded in 1993 and headquartered in Boca Raton, Florida, the company also has offices in Quincy, Massachusetts, and Bengaluru and Coimbatore, India.

Drug Abuse Sciences

Venture Round in 1999
Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.